GRAIL, Inc.

GRAL

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Baker Bros. Advisors Perceptive Advisors RA Capital Management

Catalysts

No catalysts tracked.

Activist Filings

SC 13GBaker Bros. Advisors5.3%Feb 17, 2026

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 2,085,333Value: $178.5M

## Signal Note: Baker Bros. Initiates Massive Position in GRAIL (GRAL) The reported position value of ~$178.5 billion is almost certainly a data error (likely reflecting a filing quirk or price miscalculation), but the underlying signal — Baker Bros. initiating a new 2.09M share stake in GRAIL — is noteworthy. GRAIL's core asset is Galleri, a multi-cancer early detection (MCED) blood test capable of screening for 50+ cancer types, with the company pursuing an FDA PMA submission and awaiting a potential Medicare coverage decision, both of which represent major binary catalysts. Baker Bros. running an extremely concentrated book and opening a new position in GRAIL suggests high conviction around the regulatory/reimbursement pathway for Galleri, likely timed ahead of expected FDA and CMS milestones — investors should verify the dollar value but

Perceptive AdvisorsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

BCRX3 funds SION3 funds CTNM3 funds IRON3 funds EWTX3 funds SYRE3 funds RYTM3 funds NUVL

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Perceptive Advisors Initiates GRAIL Position Edelman's $20.3M entry into GRAIL suggests confidence in the company's multi-cancer early detection platform, likely ahead of near-term clinical or commercial catalysts (Galleri blood test expansion, reimbursement decisions, or partnership announcements). Perceptive's strong clinical-stage track record indicates conviction in GRAIL's technology differentiation versus competitors in the liquid biopsy space, though the company faces execution risk on clinical validation and payer adoption.